Literature DB >> 16622614

Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature.

A Girolami1, F Tezza, M Scapin, S Vettore, A Casonato.   

Abstract

All patients with von Willebrand's disease (vWD) who showed an arterial or venous thrombosis and were reported in the literature have been evaluated. 11 patients had arterial thrombosis while 19 had venous thrombosis for a total of 30 cases. 9 out the 11 cases with arterial thrombosis had myocardial infarction. Two had cerebral thrombosis. Associated risk factors for arterial thrombosis were available only for three patients who showed, respectively, smoking and dyslipidemia (2 cases) and smoking and intravenous desmopressin infusion (1 case). The majority of patients with venous thrombosis showed DVT with or without PE. Four patients presented with apparently isolated PE. In two instances thrombosis occurred in unusual sites (central retinal vein and portal vein, respectively). Several associated risk factors were present, mainly: infusion of FVIII or FVIII + vWF concentrates in 7 cases; surgery in 8 cases, pregnancy in 1, desmopressin infusion in 1, variable coagulation defects or polymorphisms in 5. More than one of these associated conditions were present in a few patients. The majority of vWD patients who showed thrombotic phenomena were type I patient, but in 6 cases were also type 3. The type of defect was not reported in 6 patients. As a conclusion of this review it seems safe to assume that both arterial and venous thrombosis appear rare in vWD. This is confirmed by the fact that arterial or venous thrombosis appears slightly more frequent in hemophilia A and B.

Entities:  

Mesh:

Year:  2006        PMID: 16622614     DOI: 10.1007/s11239-006-5732-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

1.  Deep venous thrombosis and pulmonary embolism in a patient with type III von Willebrand's disease, protein C and antithrombin III deficiency.

Authors:  D Bowen; H Dasani; B Yung; A Bloom
Journal:  Br J Haematol       Date:  1992-07       Impact factor: 6.998

2.  Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes.

Authors:  Massimo Franchini; Mauro Krampera; Dino Veneri
Journal:  Thromb Haemost       Date:  2003-11       Impact factor: 5.249

3.  Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature.

Authors:  Karin van Dijk; Johanna G van der Bom; Kathelijn Fischer; Diederick E Grobbee; H Marijke van den Berg
Journal:  Thromb Haemost       Date:  2004-08       Impact factor: 5.249

4.  Cerebral arterial thrombosis in a young woman following vasopressin for von Willebrand's disease.

Authors:  Christopher Grainge; Tim Nokes
Journal:  Thromb Haemost       Date:  2005-02       Impact factor: 5.249

Review 5.  Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature.

Authors:  A Girolami; E Ruzzon; F Fabris; C Varvarikis; R Sartori; B Girolami
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

Review 6.  von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis.

Authors:  Ida Martinelli
Journal:  Semin Hematol       Date:  2005-01       Impact factor: 3.851

7.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Authors:  Pier M Mannucci; Juan Chediak; Wahid Hanna; John Byrnes; Marlies Ledford; Bruce M Ewenstein; Anastassios D Retzios; Barbara A Kapelan; Richard S Schwartz; Craig Kessler
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

8.  [von Willebrand's disease and coronary atherosclerosis. Apropos of 3 cases].

Authors:  M N Dulhoste; J Bonnet; C Vergnes; A Choussat; H Bricaud
Journal:  Arch Mal Coeur Vaiss       Date:  1989-11

9.  Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients.

Authors:  A Srámek; P Bucciarelli; A B Federici; P M Mannucci; V De Rosa; G Castaman; M Morfini; M G Mazzucconi; A Rocino; M Schiavoni; F A Scaraggi; J H C Reiber; F R Rosendaal
Journal:  Circulation       Date:  2004-02-17       Impact factor: 29.690

10.  Familial hypofibrinolysis and venous thrombosis.

Authors:  J Petäjä; V Rasi; G Myllylä; E Vahtera; H Hallman
Journal:  Br J Haematol       Date:  1989-03       Impact factor: 6.998

View more
  11 in total

1.  Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Federica Delaini; Vittoria Guerini; Marco Ruggeri; Francesco Rodeghiero; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

2.  Evidence-Based Minireview: Perioperative management of the VWD patient at elevated thrombotic risk.

Authors:  Holleh D Husseinzadeh; Sandra Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Congenital FVII deficiency and thrombotic events after replacement therapy.

Authors:  Antonio Girolami; Irene Bertozzi; Ignazio Rigoni; Rodolfo Muzzolon; Silvia Vettore
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

4.  Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old May-Hegglin, Sebastian, Fechtner and Epstein syndromes).

Authors:  Antonio Girolami; Girolami Antonio; Silvia Vettore; Vettore Silvia; Emanuela Bonamigo; Bonamigo Emanuela; Fabrizio Fabris; Fabris Fabrizio
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

5.  Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease.

Authors:  Mariya H Apostolova; Craig D Seaman; Diane M Comer; Jonathan G Yabes; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-21       Impact factor: 2.389

Review 6.  Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.

Authors:  A Girolami; F Tezza; R Scandellari; S Vettore; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

Review 7.  The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.

Authors:  Antonio Girolami; Nicole Candeo; Silvia Vettore; Anna Maria Lombardi; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 8.  How do you treat bleeding disorders with desmopressin?

Authors:  Bülent Ozgönenel; Madhvi Rajpurkar; Jeanne M Lusher
Journal:  Postgrad Med J       Date:  2007-03       Impact factor: 2.401

Review 9.  Von Willebrand disease in the elderly: clinical perspectives.

Authors:  John Chapin
Journal:  Clin Interv Aging       Date:  2018-08-31       Impact factor: 4.458

10.  Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.

Authors:  Elmar Raquet; Marcus Stockschlaeder; Jochen Mueller-Cohrs; Sabine Zollner; Ingo Pragst; Gerhard Dickneite
Journal:  Blood Coagul Fibrinolysis       Date:  2015-07       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.